Results 101 to 110 of about 5,710 (181)

PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment. [PDF]

Front Cardiovasc Med
Lan J, Qiu Y, Wang S, Zhang Y, Cheng S, Chen S, Xing Y.   +6 more
europepmc   +1 more source

Tafolecimab mitigates ox-LDL-induced macrophage foam cell formation and inflammation by modulating SR-A/ABCG1 expression and inhibiting the NF-κB/MAPK pathways. [PDF]

Biomed Rep
Yu X, Liu X, Dang Y, Liu R.
europepmc   +1 more source

Comment on "Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials". [PDF]

Int J Cardiol Cardiovasc Risk Prev
Gupta V, Ratnakar PJ, Shridevi K, Gaurav, Paul JR.   +4 more
europepmc   +1 more source

A retrospective study of disproportionality analysis signals between proprotein convertase subtilisin/kexin 9 inhibitor use and respiratory, thoracic, and mediastinal disorders. [PDF]

Medicine (Baltimore)
Chen H, Li L.
europepmc   +1 more source

Multidimensional lipid and inflammatory risk control following evolocumab treatment in real-world ASCVD: a hospital-based cohort study. [PDF]

Front Pharmacol
Niu Q, Liu X, Zhang H, Wang Q, Li B.
europepmc   +1 more source

Correction: A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]

Front Pharmacol
Liu HH, Li S, Li JJ.
europepmc   +1 more source

Suppression of Early TNF-Alpha Increase by a Single Evolocumab Dose in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. [PDF]

J Clin Med
Patti G, Bosco M, Marengo A, Cumitini L, Grisafi L, D'Amario D, Solli M, Mennuni M.   +7 more
europepmc   +1 more source

PCSK9 Inhibitor Attenuates Platelet TLR4 in ACS and TLR4 Blockers Prevent PCSK9-Mediated Platelet Activation. [PDF]

Acta Cardiol Sin
Qi L, Yuan M, Liu X, Liu T, Zhang Y, Chen K.   +5 more
europepmc   +1 more source

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia. [PDF]

Atheroscler Plus
Tada H, Takeji Y, Takamura M.
europepmc   +1 more source

Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets. [PDF]

Front Med (Lausanne)
Ponte-Negretti CI, Lorenzatti A, Wyss-Quintana F, Alonso R, Méndez-Castillo M, Valdez-Tiburcio O, Ullauri-Solórzano VE, Ullauri-Valcárcel CY, Puente-Barragán A, Zárate-Correa LC, Prieto-Marín JG, Sangucho IAS, Vasconez-Gonzalez J, Ortiz-Prado E.   +13 more
europepmc   +1 more source